The present invention provides compositions and methods for the treatment of herpes virus infections. In one aspect the invention provides a combination therapy for treating a herpes virus infection comprising the administration to a subject of an anti-herpes virus agent in combination with a cyclooxygenase-2 selective inhibitor. In another aspect the invention provides a mono therapy for treating a herpes virus infection comprising administering a cyclooxygenase-2 selective inhibitor to a subje...

The present invention provides compositions and methods for the treatment of herpes virus infections. In one aspect the invention provides a combination therapy for treating a herpes virus infection comprising the administration to a subject of an anti-herpes virus agent in combination with a cyclooxygenase-2 selective inhibitor. In another aspect the invention provides a mono therapy for treating a herpes virus infection comprising administering a cyclooxygenase-2 selective inhibitor to a subje...

La presente se caracteriza por un método para el tratamiento de un paciente diagnosticado o con riesgo de desarrollar un desorden inmunoinflamatorio por la administración de un SSRI o análogo o metabolito del mismo y opcionalmente un corticosteroide u otro compuesto al paciente. La presente asimismo se caracteriza por una composición farmacéutica que contiene un SSRI o análogo o metabolito del mismo y un corticosteroide u otro compuesto para el tratamiento o prevención de un desorden inmunoinfla...

The present invention relates to synergistic combinations of the compounds of formula (I) such as compounds of the xanthenone acetic acid class such as 5,6dimethylxanthenone-4-acetic acid (DMXAA) and a selective COX-2 inhibitor, in particular rofecoxib, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical formulations containing said combinations.

This innovation deals with the newly developed preparation method of new pharmaceutical dosage forms that contain the active substance rofecoxib and that are orally administrated. Owing to the development of this formulation, the dissolution properties and the in vivo characteristics of rofecoxib have been improved.

The present invention provides a simplified and commercial scale process for the manufacture of Rofecoxib. The invention comprises of oxidizing 4-(4-methylthiophenyl)-3-phenyl-2(5H)-furanone using hydrogen peroxide as oxidant, acetic acid as solvent and sodium tungstate as catalyst under suitable reaction conditions to get rofecoxib.

Mixture (X) of at least one analgesic (A) and an inhibitor (B) of cyclo-oxygenase II (COXII). - Mixture (X) of at least one analgesic (A) and an inhibitor (B) of cyclo-oxygenase II (COXII), where (A) is a phenyl-substituted tertiary amine of formulae (I)-(III), as racemates, pure or mixed stereoisomers (particularly enantiomers or diastereoisomers), optionally in the form of acids, bases, salts or solvates, preferably hydrates. - X = hydroxy, fluoro, chloro, hydrogen or OCOR7